Travere Therapeutics获美国专利商标局关于Filspari® (Sparsentan)治疗IgA肾病特定使用方法的专利申请许可通知

美股速递05-28

Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1173466257?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-28 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173466257","market":"us","top_or_hot":-1,"title":"Travere Therapeutics获美国专利商标局关于Filspari® (Sparsentan)治疗IgA肾病特定使用方法的专利申请许可通知","media":"美股速递","content":"<p>Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics获美国专利商标局关于Filspari® (Sparsentan)治疗IgA肾病特定使用方法的专利申请许可通知</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics获美国专利商标局关于Filspari® (Sparsentan)治疗IgA肾病特定使用方法的专利申请许可通知\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-28 04:18 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1173466257","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173466257","pubTimestamp":1779913126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","TVTX":"Travere Therapeutics, Inc."},"translate_title":"Travere Therapeutics obtains Filspari from U.S. Patent and Trademark Office ® (Sparsentan) Patent Application License Notice for Specific Methods of Use in the Treatment of IgA Nephropathy","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173466257","isCrawlerRequest":true}